Skip to main content

Table 3 Clinical characteristics of 12 CAEBV patients

From: Chronic active Epstein-Barr virus infection involving gastrointestinal tract mimicking inflammatory bowel disease

NO

Sex

Age ranges

Course of disease

Symptoms

EBV-DNA (copies/ml)

Surgery

Medicine

Prognosis

1

1

20–30

3 years

Fever, hematochezia

4.34*10^6

NO

Steroids, antibiotics and antiviral-drugs

Dead

2

1

50–60

3 months

Fever, vomiting, diarrhea

NA

NO

Steroids, antibiotics and thalidomide

Dead

3

1

40–50

4 months

Fever, hematochezia

NA

NO

Steroids, antiviral-drugs and immunoglobulin

Dead

4

1

40–50

3 years

Fever, vomiting, diarrhea

4.0*10^7

NO

Steroids and immunoglobulin

Dead

5

1

30–40

2 months

Fever, hematochezia

1.14*10^7

NO

Steroids and antivirus

Dead

6

1

40–50

2 years

Fever, hematochezia

1.22*10^5

YES

Steroids

Dead

7

1

20–30

1 year

Fever, diarrhea

1.54*10^6

NO

Steroids

Dead

8

2

30–40

3 years

Fever, vomiting, abdominal pain, diarrhea

3.12*10^5

NO

Steroids, antiviral-drugs and immunoglobulin

Dead

9

1

40–50

17 months

Fever, abdominal pain

1.09*10^3

YES

Steroids, antiviral-drugs

Dead

10

1

40–50

2 months

Fever, abdominal pain, hematochezia

1.29*10^6

NO

Steroids

Survive

11

1

50–60

1 month

Fever, abdominal pain, diarrhea

1.85*10^4

NO

Steroids and hemopoietic stem cell transplantation

Survive

12

1

70–80

3 months

Fever, diarrhea, hematochezia

1.63*10^6

NO

Steroids and antibiotics

Dead

  1. In consideration for patients’anonymity, we amend sex from “male” and “female” to “1” and “2”for publication